A federal experimental medicines access law aims to skirt FDA regulations, but academic medical centers still should consider imposing their own gatekeeping mechanisms, a research attorney noted.
The law, commonly known as right-to-try, gives patients with life-threatening conditions the chance to try unapproved drugs, but doesn’t mention how institutions’ oversight functions factor into the process, Verrill Dana, LLP attorney Kate Gallin Heffernan told a group of health lawyers.
“That’s up to you if you want to think about right-to-try as an option,” she said, but advised institutions to create policies and procedures to avoid potential risks rather than just alerting ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.